German pharma giant Boehringer Ingelheim has wrapped up the $76 million expansion of its pets vaccines production facility at Athens in Georgia, US.

The investment doubles the capacity of Boehringer Ingelheim to produce vaccines for pets in the US and across the world two times.

Expansion of the pets vaccines production plant was announced in December 2017 to increase its footprint of around 350,000 square feet to 400,000 square feet. The project was aimed to nearly double the filling capacity for companion animal and avian vaccines.

Commenting on the expansion of the pets vaccines production facility, Everett Hoekstra – Boehringer Ingelheim Animal Health USA president said: “Today’s announcement is representative of the growth and investment Boehringer Ingelheim is making around the United States. It also signals our commitment to a world in which no animal suffers from a preventable disease.

“We are excited about what’s in store for our company and our communities, and for the future of animal health.”

US Senator David Perdue, who visited the pets vaccines production plant said: “Boehringer Ingelheim continues to be a strong contributor to our economy. Their investment in Georgia is a testament to our outstanding universities, growing biosciences industry, and business-friendly climate.”

Boehringer Ingelheim has a workforce of around 440 people at the pets vaccines production facility in Athens, which was established in 1989. The pets vaccines production plant manufactures over 150 vaccines for pets, poultry, and also wildlife, which are sold across 80 plus countries, to protect animals from rabies and other diseases.

The Athens pets vaccines production facility is said to produce several hundred million doses of vaccines annually.

  Athens, Boehringer Ingelheim, Boehringer Ingelheim Animal Health USA, David Perdue, Everett Hoekstra, Georgia, USA, Vaccines, vaccines production facility